-
Coronavirus replication–transcription complex: Vital and selective NMPylation of a conserved site in nsp9 by the NiRAN-RdRp subunit
(Hinzugefügt: 26.01.2021 um 10:21 Uhr)
https://www.pnas.org/content/118/6/e2022310118
-
Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A
(Hinzugefügt: 26.01.2021 um 09:08 Uhr)
https://science.sciencemag.org/content/early/2021/01/22/science.abf4058.full
-
Host-directed therapies against early-lineage SARS-CoV-2 retain efficacy against B.1.1.7 variant
(Hinzugefügt: 26.01.2021 um 09:08 Uhr)
https://www.biorxiv.org/content/10.1101/2021.01.24.427991v1
-
Woran die Pharmabranche forscht Schwierige Suche nach Covid-Medikamenten
(Hinzugefügt: 25.01.2021 um 12:48 Uhr)
https://www.tagesschau.de/wirtschaft/corona-medikament-101.html
-
Fecal microbiota transplantation for COVID-19; a potential emerging treatment strategy
(Hinzugefügt: 24.01.2021 um 18:31 Uhr)
https://www.sciencedirect.com/science/article/pii/S0306987720333673
-
N-Acetylcysteine to Combat COVID-19: An Evidence Review
(Hinzugefügt: 24.01.2021 um 18:26 Uhr)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7649937/
-
Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents
(Hinzugefügt: 22.01.2021 um 21:44 Uhr)
https://www.nature.com/articles/s42003-020-01577-x
-
α1-Antitrypsin deficiency and the risk of COVID-19: an urgent call to action
(Hinzugefügt: 22.01.2021 um 09:25 Uhr)
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00018-7/fulltext
-
GABA administration prevents severe illness and death following coronavirus infection in mice
(Hinzugefügt: 20.01.2021 um 09:04 Uhr)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7536896/pdf/nihpp-2020.10.04.325423.pdf
-
COVID-19—The Potential Beneficial Therapeutic Effects of Spironolactone during SARS-CoV-2 Infection
(Hinzugefügt: 18.01.2021 um 07:15 Uhr)
https://www.mdpi.com/1424-8247/14/1/71
-
Artemisia annua L. extracts prevent in vitro replication of SARS-CoV-2
(Hinzugefügt: 13.01.2021 um 08:24 Uhr)
https://www.biorxiv.org/content/10.1101/2021.01.08.425825v1
-
Enisamium is an inhibitor of the SARS-CoV-2 RNA polymerase and shows improvement of recovery in COVID-19 patients in an interim analysis of a clinical trial
(Hinzugefügt: 13.01.2021 um 08:01 Uhr)
https://www.medrxiv.org/content/10.1101/2021.01.05.21249237v1
-
The hyperlipidaemic drug fenofibrate significantly reduces infection by SARS-CoV-2 in cell culture models
(Hinzugefügt: 12.01.2021 um 20:36 Uhr)
https://www.biorxiv.org/content/10.1101/2021.01.10.426114v1
-
Antiviral drugs in hospitalized patients with COVID-19 - the DisCoVeRy trial
(Hinzugefügt: 11.01.2021 um 08:15 Uhr)
https://www.medrxiv.org/content/10.1101/2021.01.08.20248149v1
-
Repurposing of CNS drugs to treat COVID-19 infection: targeting the sigma-1 receptor
(Hinzugefügt: 10.01.2021 um 09:15 Uhr)
https://link.springer.com/article/10.1007/s00406-020-01231-x
-
Impact of colchicine on mortality in patients with COVID-19. A meta-analysis.
(Hinzugefügt: 08.01.2021 um 10:18 Uhr)
https://www.sciencedirect.com/science/article/pii/S1109966620302852
-
Quercetin: Antiviral Significance and Possible COVID-19 Integrative Considerations
(Hinzugefügt: 08.01.2021 um 09:44 Uhr)
https://journals.sagepub.com/doi/full/10.1177/1934578X20976293
-
Existing antihistamine drugs show effectiveness against COVID-19 virus in cell testing
(Hinzugefügt: 07.01.2021 um 05:27 Uhr)
https://m.ufhealth.org/news/2020/existing-antihistamine-drugs-show-effectiveness-against-covid-19-virus-cell-testing
-
FBA reveals guanylate kinase as a potential target for antiviral therapies against SARS-CoV-2
(Hinzugefügt: 06.01.2021 um 08:42 Uhr)
https://academic.oup.com/bioinformatics/article/36/Supplement_2/i813/6055936
-
Guanylatkinase (GK1) SARS-CoV-2: Bioinformatiker entdecken eine neue Schwachstelle des Virus
(Hinzugefügt: 06.01.2021 um 08:41 Uhr)
https://www.dzif.de/de/sars-cov-2-bioinformatiker-entdecken-eine-neue-schwachstelle-des-virus-0
-
Umbilical stem cells show promise against severe COVID-19
(Hinzugefügt: 06.01.2021 um 08:36 Uhr)
https://www.upi.com/Health_News/2021/01/05/Umbilical-stem-cells-show-promise-against-severe-COVID-19/1611609873569/
-
CoViTris2020 and ChloViD2020: a striking new hope in COVID-19 therapy
(Hinzugefügt: 06.01.2021 um 08:26 Uhr)
https://link.springer.com/article/10.1007/s11030-020-10169-0
-
Umbilical cord mesenchymal stem cells for COVID‐19 acute respiratory distress syndrome: A double‐blind, phase 1/2a, randomized controlled trial
(Hinzugefügt: 06.01.2021 um 08:25 Uhr)
https://stemcellsjournals.onlinelibrary.wiley.com/doi/10.1002/sctm.20-0472
-
Amantadin has potential for the treatment of COVID-19 because it targets known and novel ion channels encoded by SARS-CoV-2
(Hinzugefügt: 05.01.2021 um 08:17 Uhr)
https://www.researchsquare.com/article/rs-121743/v1
-
SARS-CoV-2: ACE-Hemmer könnten Risiko auf schweren Krankheitsverlauf senken
(Hinzugefügt: 05.01.2021 um 08:06 Uhr)
https://www.aerzteblatt.de/nachrichten/119841/SARS-CoV-2-ACE-Hemmer-koennten-Risiko-auf-schweren-Krankheitsverlauf-senken
-
Mushroom-derived bioactive compounds potentially serve as the inhibitors of SARS-CoV-2 main protease: an in silico approach
(Hinzugefügt: 04.01.2021 um 18:55 Uhr)
https://www.sciencedirect.com/science/article/pii/S2225411021000018
-
Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19
(Hinzugefügt: 03.01.2021 um 20:00 Uhr)
https://jamanetwork.com/journals/jama/fullarticle/2773108?utm_source=twitter&utm_campaign=content-shareicons&utm_content=article_engagement&utm_medium=social&utm_term=010321#.X_F_xDqfFcE
-
Pyrrolo[2,3-b]quinoxalines in attenuating cytokine storm in COVID-19: their sonochemical synthesis and in silico / in vitro assessment
(Hinzugefügt: 03.01.2021 um 19:57 Uhr)
https://www.sciencedirect.com/science/article/abs/pii/S0022286020321815
-
Large population study identifies drugs associated with reduced COVID-19 severity
(Hinzugefügt: 01.01.2021 um 19:20 Uhr)
https://www.medrxiv.org/content/10.1101/2020.10.13.20211953v2
-
Higher Survival Rate Associated with Thymosin Alpha 1 use in Critical COVID-19: A Retrospective Multicenter Cohort Study
(Hinzugefügt: 30.12.2020 um 08:06 Uhr)
https://www.researchsquare.com/article/rs-123265/v1
-
SARS-CoV-2 infection: can ferroptosis be a potential treatment target for multiple organ involvement?
(Hinzugefügt: 30.12.2020 um 08:05 Uhr)
https://pubmed.ncbi.nlm.nih.gov/33298888/
-
Comparing ICU Admission Rates of Mild/Moderate COVID-19 Patients Treated with Hydroxychloroquine, Favipiravir, and Hydroxychloroquine plus Favipiravir
(Hinzugefügt: 30.12.2020 um 07:57 Uhr)
https://www.sciencedirect.com/science/article/pii/S1876034120307735
-
Induction of alarmin S100A8/A9 mediates activation of aberrant neutrophils in the pathogenesis of COVID-19
(Hinzugefügt: 29.12.2020 um 09:39 Uhr)
https://www.cell.com/cell-host-microbe/fulltext/S1931-3128(20)30679-X
-
Bosnian company produces drug that accelerates COVID-19 recovery process
(Hinzugefügt: 26.12.2020 um 10:01 Uhr)
http://ba.n1info.com/English/NEWS/a498471/Bosnian-company-produces-drug-that-accelerates-COVID-19-recovery-process.html
-
Human SARS-CoV-2 neutralizing antibody COR-101 demonstrates high efficacy in a COVID-19 animal model and is ready to be used in clinical studies to treat COVID-19 patients
(Hinzugefügt: 22.12.2020 um 07:24 Uhr)
http://corat-therapeutics.com/wp-content/uploads/2020/12/PR_2020.12.04_CORAT_COR-101-demonstrates-high-efficacy-in-a-COVID-19-animal-model.pdf
-
Can Activation of NRF2 Be a Strategy against COVID-19?
(Hinzugefügt: 19.12.2020 um 12:06 Uhr)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7359808/
-
Synairgen plc SNG001 given Fast Track designation and IND cleared by the US FDA
(Hinzugefügt: 18.12.2020 um 21:44 Uhr)
https://www.globenewswire.com/news-release/2020/12/18/2147530/0/en/COVID-19-Clinical-Programme-Update.html
-
Lycorine, a non-nucleoside RNA dependent RNA polymerase inhibitor, as potential treatment for emerging coronavirus infections
(Hinzugefügt: 18.12.2020 um 10:37 Uhr)
https://www.sciencedirect.com/science/article/pii/S0944711320302713
-
Foistar(Camostat mesylate) associated with the significant decrease in CRP levels compared to Kaletra(Lopinavir/Ritonavir) treatment in Korean mild COVID-19 pneumonic patients.
(Hinzugefügt: 17.12.2020 um 08:35 Uhr)
https://www.medrxiv.org/content/10.1101/2020.12.10.20240689v1
-
Cholesterol 25-hydroxylase suppresses SARS-CoV-2 replication by blocking membrane fusion
(Hinzugefügt: 16.12.2020 um 18:51 Uhr)
https://www.pnas.org/content/117/50/32105
-
Aprotinin Inhibits SARS-CoV-2 Replication
(Hinzugefügt: 16.12.2020 um 08:06 Uhr)
https://www.mdpi.com/2073-4409/9/11/2377
-
Thalidomide Combined with Short-term Low-Dose Glucocorticoid Therapy for the Treatment of Severe COVID-19: A Case-Series Study
(Hinzugefügt: 15.12.2020 um 19:01 Uhr)
https://www.sciencedirect.com/science/article/pii/S1201971220325467
-
Hepatitis C Virus Drugs Simeprevir and Grazoprevir Synergize with Remdesivir to Suppress SARS-CoV-2 Replication in Cell Culture
(Hinzugefügt: 15.12.2020 um 19:01 Uhr)
https://www.biorxiv.org/content/10.1101/2020.12.13.422511v1
-
A retrospective comparison of drugs against COVID-19
(Hinzugefügt: 15.12.2020 um 09:54 Uhr)
https://www.sciencedirect.com/science/article/abs/pii/S0168170220311692
-
RECOVERY trial finds no benefit from azithromycin in patients hospitalised with COVID-19
(Hinzugefügt: 14.12.2020 um 18:37 Uhr)
https://www.recoverytrial.net/news/recovery-trial-finds-no-benefit-from-azithromycin-in-patients-hospitalised-with-covid-19
-
Results of Open-Label non-Randomized Comparative Clinical Trial: “BromhexIne and Spironolactone for CoronаvirUs Infection requiring hospiTalization (BISCUIT)
(Hinzugefügt: 14.12.2020 um 07:17 Uhr)
https://lib.ossn.ru/jour/article/view/1440/
-
Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets
(Hinzugefügt: 13.12.2020 um 15:25 Uhr)
https://www.nature.com/articles/s41564-020-00835-2
-
Rationale for COVID-19 Treatment by Nebulized Interferon-β-1b–Literature Review and Personal Preliminary Experience
(Hinzugefügt: 13.12.2020 um 10:40 Uhr)
https://www.frontiersin.org/articles/10.3389/fphar.2020.592543/full
-
Sulodexide in the treatment of patients with early stages of COVID-19: a randomised controlled trial
(Hinzugefügt: 09.12.2020 um 18:44 Uhr)
https://www.medrxiv.org/content/10.1101/2020.12.04.20242073v1
-
PDF [320 KB] Save Share Reprints Request Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019
(Hinzugefügt: 09.12.2020 um 18:41 Uhr)
https://journal.chestnet.org/article/S0012-3692(20)34898-4/fulltext
-
Metformin and risk of mortality in patients hospitalised with COVID-19: a retrospective cohort analysis
(Hinzugefügt: 09.12.2020 um 09:08 Uhr)
https://www.sciencedirect.com/science/article/pii/S2666756820300337?via%3Dihub#!
-
Molnupiravir (4482/EIDD-2801) Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets
(Hinzugefügt: 09.12.2020 um 09:07 Uhr)
https://www.nature.com/articles/s41564-020-00835-2
-
COVID-19: Metformin könnte Sterberisiko bei Frauen mit Typ-2-Diabetes senken
(Hinzugefügt: 09.12.2020 um 00:33 Uhr)
https://www.aerzteblatt.de/nachrichten/119145/COVID-19-Metformin-koennte-Sterberisiko-bei-Frauen-mit-Typ-2-Diabetes-senken
-
The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with mild COVID-19: a pilot, double-blind, placebo-controlled, randomized clinical trial
(Hinzugefügt: 08.12.2020 um 08:58 Uhr)
https://www.researchsquare.com/article/rs-116547/v1
-
Cyclosporine A plus low-dose steroid treatment in COVID-19 improves clinical outcomes in patients with moderate to severe disease. A pilot study
(Hinzugefügt: 07.12.2020 um 16:48 Uhr)
https://pubmed.ncbi.nlm.nih.gov/33274479/
-
Clinically Approved Antiviral Drug in an Orally Administrable Nanoparticle for COVID-19
(Hinzugefügt: 06.12.2020 um 17:08 Uhr)
https://pubs.acs.org/doi/10.1021/acsptsci.0c00179
-
Efficacy and Safety of Topical Ivermectin + IotaCarrageenan in the Prophylaxis against COVID-19 in Health Personnel
(Hinzugefügt: 06.12.2020 um 16:59 Uhr)
https://medicalpressopenaccess.com/upload/1605709669_1007.pdf
-
Malleability of the SARS-CoV-2 3CL Mpro Active-Site Cavity Facilitates Binding of Clinical Antivirals
(Hinzugefügt: 06.12.2020 um 16:55 Uhr)
https://www.cell.com/structure/fulltext/S0969-2126(20)30379-8?_r
-
Metformin and risk of mortality in patients hospitalised with COVID-19: a retrospective cohort analysis
(Hinzugefügt: 05.12.2020 um 08:30 Uhr)
https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(20)30033-7/fulltext
-
Efficacy and Safety of Molnupiravir (MK-4482) in Hospitalized Adult Participants With COVID-19 (MK-4482-001)
(Hinzugefügt: 04.12.2020 um 09:26 Uhr)
https://clinicaltrials.gov/ct2/show/NCT04575584
-
Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine and Pyronaridine: In vitro Activity Against SARS-CoV-2 and Potential Mechanisms
(Hinzugefügt: 03.12.2020 um 18:22 Uhr)
https://www.biorxiv.org/content/10.1101/2020.12.01.407361v1
-
A two-arm, randomized, controlled, multi-centric, open-label Phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19
(Hinzugefügt: 03.12.2020 um 18:20 Uhr)
https://www.medrxiv.org/content/10.1101/2020.12.01.20239574v1
-
A five day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness
(Hinzugefügt: 03.12.2020 um 12:29 Uhr)
https://www.sciencedirect.com/science/article/pii/S1201971220325066
-
Low-dose ruxolitinib plus steroid in severe SARS-CoV-2 pneumonia
(Hinzugefügt: 01.12.2020 um 08:06 Uhr)
https://www.nature.com/articles/s41375-020-01087-z
-
Ivermectin: Latin America’s embrace of an unproven COVID treatment is hindering drug trials
(Hinzugefügt: 29.11.2020 um 13:06 Uhr)
https://www.nature.com/articles/d41586-020-02958-2
-
Ivermectin: Latin America’s embrace of an unproven COVID treatment is hindering drug trials
(Hinzugefügt: 29.11.2020 um 13:06 Uhr)
https://www.nature.com/articles/d41586-020-02958-2
-
A COVID-19 Prophylaxis? Lower incidence associated with prophylactic administration of Ivermectin
(Hinzugefügt: 29.11.2020 um 13:05 Uhr)
https://www.sciencedirect.com/science/article/pii/S0924857920304684
-
VIP in the Treatment of Critical COVID-19 With Respiratory Failure in Patients With Severe Comorbidity: A Prospective Externally-Controlled Trial
(Hinzugefügt: 28.11.2020 um 12:46 Uhr)
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3665228
-
Flavonols as potential antiviral drugs targeting SARS-CoV-2 proteases (3CLpro and PLpro), spike protein, RNA-dependent RNA polymerase (RdRp) and angiotensin-converting enzyme II receptor (ACE2)
(Hinzugefügt: 27.11.2020 um 21:54 Uhr)
https://www.sciencedirect.com/science/article/abs/pii/S0014299920308517
-
Efficacy and Safety of Favipiravir, an Oral RNA-Dependent RNA Polymerase Inhibitor, in Mild-to-Moderate COVID-19: A Randomized, Comparative, Open-Label, Multicenter, Phase 3 Clinical Trial
(Hinzugefügt: 27.11.2020 um 21:53 Uhr)
https://www.sciencedirect.com/science/article/pii/S120197122032453X
-
Leronlimab
(Hinzugefügt: 27.11.2020 um 21:48 Uhr)
https://www.globenewswire.com/news-release/2020/11/23/2131590/0/en/CytoDyn-Reaches-Enrollment-Target-of-293-Patients-for-2nd-DSMC-Interim-Analysis-of-Phase-3-COVID-19-Trial-and-Expects-to-Enroll-the-Remaining-97-Patients-in-the-Next-Few-Weeks-to-C.html
-
Colchicine to be investigated as a possible treatment for COVID-19 in the RECOVERY trial
(Hinzugefügt: 27.11.2020 um 21:46 Uhr)
https://www.recoverytrial.net/news/colchicine-to-be-investigated-as-a-possible-treatment-for-covid-19-in-the-recovery-trial
-
Low-Dose Radiation Therapy (LDRT) for COVID-19: Benefits or Risks?
(Hinzugefügt: 26.11.2020 um 08:49 Uhr)
https://meridian.allenpress.com/radiation-research/article/194/5/452/445871/Low-Dose-Radiation-Therapy-LDRT-for-COVID-19
-
baricitinib/ dexamethasone
(Hinzugefügt: 26.11.2020 um 08:48 Uhr)
https://www.nih.gov/news-events/news-releases/fourth-iteration-covid-19-treatment-trial-underway
-
(AVIPTADIL) IN PATIENTS WITH CRITICAL COVID-19 AND SEVERE COMORBIDITY: 72% SURVIVAL SEEN IN ICU PATIENTS
(Hinzugefügt: 24.11.2020 um 20:44 Uhr)
https://relieftherapeutics.com/newsblog/neurorx-and-relief-announce-initial-successful-results-from-expanded-access-use-of-rlf-100-aviptadil-in-patients-with-critical-covid-19-and-severe-comorbidity-72-survival-seen-in-icu-patients
-
Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial
(Hinzugefügt: 24.11.2020 um 09:13 Uhr)
https://www.medrxiv.org/content/10.1101/2020.11.18.20234161v1
-
Nitazoxanide for Repurposing in COVID-19
(Hinzugefügt: 22.11.2020 um 09:40 Uhr)
https://www.sciencedirect.com/science/article/pii/S0014299920308402
-
Tocilizumab effective in treating sickest COVID-19 patients
(Hinzugefügt: 20.11.2020 um 09:02 Uhr)
https://www.recover-europe.eu/tocilizumab-effective-in-treating-sickest-covid-19-patients/
-
Roche's Actemra helps the sickest COVID-19 patients
(Hinzugefügt: 20.11.2020 um 08:24 Uhr)
https://www.reuters.com/article/us-roche-actemra-trial-idUSKBN27Z1WR
-
Repurposing Fostamatinib to Combat SARS-CoV-2-Induced Acute Lung Injury
(Hinzugefügt: 19.11.2020 um 08:05 Uhr)
https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(20)30189-0
-
Synergistic Effect of Quercetin and Vitamin C Against COVID-19
(Hinzugefügt: 18.11.2020 um 09:44 Uhr)
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3682517
-
Re-recognizing bromhexine hydrochloride: pharmaceutical properties and its possible role in treating pediatric COVID-19
(Hinzugefügt: 18.11.2020 um 09:13 Uhr)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7459257/
-
Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy
(Hinzugefügt: 18.11.2020 um 09:10 Uhr)
https://www.sciencedirect.com/science/article/pii/S1201971220324589
-
Ivermectin and Doxycycline
(Hinzugefügt: 17.11.2020 um 08:53 Uhr)
http://iaimjournal.com/wp-content/uploads/2020/10/iaim_2020_0710_23.pdf
-
Interferon-b trial shows positive results
(Hinzugefügt: 17.11.2020 um 08:43 Uhr)
https://oxfordbrc.nihr.ac.uk/interferon-b-trial-shows-positive-results/
-
Hinweise, dass eine frühe Therapie mit Interferon-beta-1a-Inhalation oder Fluvoxamin helfen könnte
(Hinzugefügt: 17.11.2020 um 08:42 Uhr)
https://www.aerztezeitung.de/Nachrichten/Hinweise-auf-Arzneien-fuer-fruehe-Therapie-414665.html
-
liposome-based curcumin: lipocurc to restore and boost brain health in COVID-19 syndrome
(Hinzugefügt: 16.11.2020 um 12:26 Uhr)
https://www.sciencedirect.com/science/article/pii/B9780128205938000185
-
Use of Ivermectin in the Prophylaxis and Treatment of COVID-19
(Hinzugefügt: 15.11.2020 um 09:11 Uhr)
https://osf.io/wx3zn/
-
Efficacy and Safety of Ivermectin for Treatment and prophylaxis
(Hinzugefügt: 14.11.2020 um 19:21 Uhr)
https://www.researchsquare.com/article/rs-100956/v1
-
NIHR-supported phase 3 trial of nebulised interferon beta
(Hinzugefügt: 14.11.2020 um 10:56 Uhr)
https://www.nihr.ac.uk/news/covid-19-treatment-results-published-in-journal-ahead-of-nihr-supported-phase-3-trial-of-nebulised-interferon-beta/26186
-
Antidepressivum Fluvoxamin
(Hinzugefügt: 14.11.2020 um 10:42 Uhr)
https://www.aerzteblatt.de/nachrichten/118369/SARS-CoV-2-Kann-ein-Antidepressivum-den-Verlauf-der-Erkrankung-abschwaechen
-
Nebulised interferon beta-1a for patients with COVID-19
(Hinzugefügt: 13.11.2020 um 08:46 Uhr)
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30523-3/fulltext
-
Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001)
(Hinzugefügt: 13.11.2020 um 08:36 Uhr)
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30511-7/fulltext
-
Fluvoxamine vs Placebo and Clinical Deterioration
(Hinzugefügt: 13.11.2020 um 08:20 Uhr)
https://jamanetwork.com/journals/jama/fullarticle/2773108
-
is there a role for bromhexine as add-on therapy?
(Hinzugefügt: 12.11.2020 um 17:43 Uhr)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7249615/
-
COVID-19 Patients Receiving Compassionate Use Leronlimab
(Hinzugefügt: 12.11.2020 um 08:10 Uhr)
https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1583/5932277
-
High-Dose Ivermectin in Adults
(Hinzugefügt: 12.11.2020 um 08:04 Uhr)
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3714649
-
Alkaloide
(Hinzugefügt: 10.11.2020 um 07:47 Uhr)
https://www.sciencedirect.com/science/article/pii/S0009279720316756
-
PPI / Magenschutz
(Hinzugefügt: 09.11.2020 um 07:08 Uhr)
https://onlinelibrary.wiley.com/doi/full/10.1111/joim.13183
-
Artemisinin-Piperaquine
(Hinzugefügt: 08.11.2020 um 11:54 Uhr)
https://www.sciencedirect.com/science/article/pii/S0924857920304271
-
ACE2 (hrsACE2)
(Hinzugefügt: 06.11.2020 um 07:57 Uhr)
https://www.nature.com/articles/s41392-020-00374-6/
-
Intranasal fusion inhibitory lipopeptide
(Hinzugefügt: 05.11.2020 um 12:29 Uhr)
https://www.biorxiv.org/content/10.1101/2020.11.04.361154v1
-
Ivermectin
(Hinzugefügt: 05.11.2020 um 12:29 Uhr)
https://www.trialsitenews.com/real-world-evidence-i-mask-protocol-ivermectin-key-for-prophylaxis-and-early-treatment-of-covid-19/
-
Interferon
(Hinzugefügt: 05.11.2020 um 08:00 Uhr)
https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001023-14/GB
-
synthetic nanobody
(Hinzugefügt: 05.11.2020 um 07:32 Uhr)
https://www.biorxiv.org/content/10.1101/2020.08.08.238469v2
-
Aprotinin Inhibits SARS-CoV-2 Replication
(Hinzugefügt: 05.11.2020 um 07:22 Uhr)
https://www.mdpi.com/2073-4409/9/11/2377
-
Famotidin
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.medrxiv.org/content/10.1101/2020.09.28.20203463v1
-
Colchicine
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.hindawi.com/journals/cjidmm/2020/8865954/
-
cetirizine - famotidine
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.sciencedirect.com/science/article/pii/S1094553920301462
-
Prozac
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.tandfonline.com/doi/full/10.1080/22221751.2020.1829082
-
Nicotin
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3677428
-
Prozac
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.n-tv.de/wissen/Prozac-wirkt-gegen-Covid-19-article22120075.html
-
Azelastin
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.biorxiv.org/content/10.1101/2020.09.15.296228v1
-
Candesartan
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.sciencedirect.com/science/article/pii/S0753332220308465
-
Statine
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.sciencedaily.com/releases/2020/09/200923164603.htm
-
EIDD-2801
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.researchsquare.com/article/rs-80404/v1
-
Doxycyclin
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7419149/
-
Cyclosporin
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.sciencedirect.com/science/article/pii/S2589537020303357
-
Favipiravir
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.trialsitenews.com/fujifilm-toyama-chemical-co-submits-application-for-avigan-favipiravir-approval-for-covid-19-to-japans-health-authority/
-
getestete Medikamente
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.frontiersin.org/articles/10.3389/fmed.2020.552991/full